This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


GlaxoSmithKline plc

Drug Names(s): Avandamet XR, avandia and metformin, rosiglitazone maleate and metformin HCl

Description: AVANDAMET combines 2 antidiabetic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: rosiglitazone and metformin. Rosiglitazone, a thiazolidinedione, is an agonist for the peroxisome proliferator–activated receptor-gamma (PPAR gamma) and improves insulin sensitivity. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Though not definitively established, recent evidence suggests its intracellular target is AMP-activated protein kinase.

Avandamet News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug